ACUTE PAEDIATRIC PRESENTATION WITH COVID-19

MODULE: CORONAVIRUS PREPARATION SIMULATION

BACKGROUND:

Coronaviruses comprise a vast family of viruses, 7 of which are known to cause disease in humans. Some coronaviruses that typically infect animals have been known to evolve to infect humans. SARS-CoV-2 is likely one such virus, postulated to have originated in a large animal and seafood market. Recent cases involve individuals who reported no contact with animal markets, suggesting that the virus is now spreading from person to person.

Severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) are also caused by coronaviruses that "jumped" from animals to humans. More than 8,000 individuals developed SARS, nearly 800 of whom died of the illness (mortality rate of approximately 10%), before it was controlled in 2003. MERS continues to resurface in sporadic cases. A total of 2,465 laboratory-confirmed cases of MERS have been reported since 2012, resulting in 850 deaths (mortality rate of 34.5%).
The full genome of SARS-CoV-2 was first posted by Chinese health authorities soon after the initial detection, facilitating viral characterization and diagnosis. The CDC analyzed the genome from the first US patient who developed the infection on January 24, 2020, concluding that the sequence is nearly identical to the sequences reported by China. SARS-CoV-2 is a group 2b beta-coronavirus that has at least 70% similarity in genetic sequence to SARS-CoV. Like MERS-CoV and SARS-CoV, SARS-CoV-2 originated in bats.

Early reports have described COVID-19 as clinically milder than MERS or SARS in terms of severity and case fatality rate. Thus far, the fatality rate for COVID-19 appears to be around 2%.

Early in the outbreak, WHO reported that severe cases in China had mostly been reported in adults older than 40 years old with significant comorbidities and skewed toward men, although this pattern may be changing.

In an initial report of 41 patients infected in Wuhan, China, Huang et al reported a 78% male predominance, with 32% of all patients reporting underlying disease. The most common clinic finding was fever (98%), followed by cough (76%) and myalgia/fatigue (44%). Headache, sputum production, and diarrhea were less common. The clinical course was characterized by the development of dyspnea in 55% of patients and lymphopenia in 66%. All patients with pneumonia had abnormal lung imaging findings. Acute respiratory distress syndrome (ARDS) developed in 29% of patients, and ground-glass opacities are common on CT scans.

David J Cennimo, MD, FAAP, FACP, AAHIVS Assistant Professor of Medicine and Pediatrics, Adult and Pediatric Infectious Diseases, Rutgers New Jersey Medical School

https://emedicine.medscape.com/article/2500114-overview#a2

INFORMATION FOR FACULTY

LEARNING OBJECTIVES

- To test the processes surrounding a child presenting acutely to an Emergency Department with suspected COVID-19 and respiratory distress
- To test infection prevention and isolation procedures
- To test PPE donning and doffing in the acute setting
- To test basic acute respiratory management with the added challenges of COVID-19 isolation restrictions
- To test transport procedures between wards
- To test intubation in the deteriorating child with isolation procedures

SCENE SETTING

- Location: Emergency Department +/- Isolation Paediatric ward
- Expected Duration:
    - Scenario 1 hour
    - Debrief 1 hour

EQUIPMENT AND CONSUMABLES

Simulation Monitoring
Mannequin
Monitoring Equipment
O2 Mask
Nebuliser circuit
PPE

- Facemasks
- Visors
- Gowns
- Gloves
- Surgical hats

Transfer monitor and equipment
Bag Valve Mask/Ayres T-Piece
Respiratory Drug Pack

- Salbutamol (Nebules/IV)
- Ipratropium Nebules
- IV Aminophylline
- IV Magnesium Sulphate

Resuscitation Drug Pack
Blood Gas (see appendix)
CXR (see appendix)

PERSONNEL-IN-SCENARIO

This is a complex scenario involving a large number of personnel. Numbers of staff will vary for each department, but should include representatives from:

Nursing
ED medical team
Paediatric medical team
Security team
ED administration team

PARTICIPANT BRIEFING

You are called urgently to ED to see Monty, a 7 year old boy who has been brought to ED by his parents. Monty has developed difficulty in breathing and wheeze over the past 24 hours. He has no previous history of wheeze. Monty returned from Northern Italy 2 weeks ago following a skiing trip.

Monty is previously fit and well with no previous admissions to hospital. He does not take any regular medications.

Monty has been moved to ED resus and the ED triage nurse has recommended the use of full COVID-19 PPE in view of his recent travel history and current symptoms.

Please review Monty and treat him as appropriate ensuring that isolation procedures are carried out throughout your management.

ADDITIONAL INFORMATION

WETFlAG Calculation

W – 22kg
E – 4J/kg = 88J
T – (Age/4) + 4 = 5.0, 5.5, 6.0
Fl – 20ml/kg = 440ml 0.9% saline
A – 0.1ml/kg 1:10,000 = 2.2ml
G – 2ml/kg 10% Dextrose = 44ml

CONDUCT OF SCENARIO

Initial State

A	Patent	D	GCS 15/15 Alert but quiet
B	Sats 90% in air, RR 40 Increased work of breathing Prolonged expiratory phase Crepitations and wheeze bilaterally	E	Temperature 39.5oC No Rash Abdomen Soft and Non-tender
C	HR 150, BP 126/84 Capillary Refill <2 seconds Normal heart sounds		

Initial Expected Management

Resource/Environment Management

- Ensure isolation of patient with defined 'hot' (within 2 metres of patient) and 'cold' zones of resus area
- Allocate 'hot' and 'cold' team to manage scenario
- 'Hot' team to don full PPE as per PHE guidance
- Ensure movement of personnel and equipment between 'hot' and 'cold' zones is controlled with isolation precautions

Clinical Management

- Assess patient
- Apply high flow oxygen via facemask
- Treat acute wheeze with nebulisers as per SORT guidelines
- Blood gas (if taken) – Appendix 1

- Some improvement following nebulisers
- HR 155, RR 30, Sats 100% with oxygen
- Ongoing increased work of breathing
- Evidence of tremor and early salbutamol toxicity

→

- Ongoing management as per SORT guidelines
- Started on IV bronchodilator in resus
- Continues regular nebulisers
- CXR (if taken) – Appendix 2
- Repeat blood gas following interventions – Appendix 3

- Moved to appropriate ward environment to accommodate FFP3 isolation procedures as per local Trust guidelines
- Team to follow local guidelines for movement of isolated patient through hospital. This may involve:
  - Security team clearing public areas to allow free movement of patient and team
  - Patients in ward environment moved to allow isolation space with donning and doffing areas for staff
- Consider the need for staff both in and out of PPE to allow safe movement through hospital

→

Time moved forward 1-2 hours

- Patient remains on IV bronchodilator, but WOB increasing
- HR 165, RR 45, Sats 91% in 15L/min oxygen
- Repeat blood gas – Appendix 4
- In view of worsening CO2, discuss with PICU
- Advised to intubate and ventilate with local anaesthetic team
- Intubate and ventilate using SORT Intubation Checklist and move to appropriate location in Trust
- Ensure correct HME filters used in ventilator
- Prepare for retrieval by SORT

Appendix 1 (First blood gas)

RADIOMETER ABL 9000 SERIES

ABL900 ED 00:00:00 08-12-2010
PATIENT REPORT Syringe S195uL Sample# 90.....

Patient ID
Patient First Name Monty
Patient Last Name Smith
Date of Birth
Sample type Capillary
Fi O_2 15L/min
Department
Operator

Blood Gas Values

pH	7.32		[7.340 - 7.450]
pCO2	5.2	kPa	[4.70 - 6.00]
pO2		kPa	[10.0 - 13.3]
pO2(A-a)e		kPa	

Oximetry Values

ctHb	126	g/dL	[12.0 - 16.0]
sO_2	90	%	[95.0 - 98.0]
FO_2Hb		%	[94.0 - 99.0]
FCOHb			[-]
FHHb		%	[-]
FmetHb		%	[0.02 - 0.06]
Hctc		%	

Electrolyte Values

cK+	5.4	mmol/L	[3.0 - 5.0]
cNa+	138	mmol/L	[136 - 146]
$cCa^{2}+$	1.2	mmeq/L	[1.15 - 1.29]
cCl-	101	mmol/L	[98 - 106]

Metabolite Values

cGlu	6.7	mmol/L	[3.5 - 10.0]
cLac	2.0	mmol/L	[0.5 - 1.6]

Acid Base Status

cBase(Ecf)c	-2.8	mmol/L
$cHCO^{3}$-(P,st)c	22	mmol/L

Notes
↑ Value (s) above reference range
↓ Value (s) below reference range
c Calculated Value (s)
e Estimated Value (s)

Appendix 2 (CXR)



Appendix 3 (Second blood gas)

RADIOMETER ABL 9000 SERIES

ABL900 ED 00:00:00 08-12-2010
PATIENT REPORT Syringe S195uL Sample# 90…..

Patient ID	
Patient First Name	Monty
Patient Last Name	Smith
Date of Birth	
Sample type	Capillary
Fi O_2	15L/min
Department	
Operator	

Blood Gas Values

pH	7.35		[7.340 - 7.450]
pCO2	4.3	kPa	[4.70 - 6.00]
pO2		kPa	[10.0 - 13.3]
pO2(A-a)e		kPa	

Oximetry Values

ctHb	125	g/dL	[12.0 - 16.0]
sO_2	97	%	[95.0 - 98.0]
FO_2Hb		%	[94.0 - 99.0]
FCOHb			[-]
FHHb		%	[-]
FmetHb		%	[0.02 - 0.06]
Hctc		%	

Electrolyte Values

cK+	4.9	mmol/L	[3.0 - 5.0]
cNa+	136	mmol/L	[136 - 146]
$cCa^{2}+$	1.1	mmeq/L	[1.15 - 1.29]
cCl-	104	mmol/L	[98 - 106]

Metabolite Values

cGlu	6.0	mmol/L	[3.5 - 10.0]
cLac	1.8	mmol/L	[0.5 - 1.6]

Acid Base Status

cBase(Ecf)c	-2.3	mmol/L
$cHCO^{3}$-(P,st)c	23	mmol/L

Notes
↑ Value (s) above reference range
↓ Value (s) below reference range
c Calculated Value (s)
e Estimated Value (s)

Appendix 4 (Third blood gas)

RADIOMETER ABL 9000 SERIES

ABL900 ED 00:00:00 08-12-2010
PATIENT REPORT Syringe S195uL Sample# 90…..

Patient ID	
Patient First Name	Monty
Patient Last Name	Smith
Date of Birth	
Sample type	Capillary
Fi O_2	15L/min
Department	
Operator	

Blood Gas Values

pH	7.21		[7.340 - 7.450]
pCO2	6.8	kPa	[4.70 - 6.00]
pO2		kPa	[10.0 - 13.3]
pO2(A-a)e		kPa	

Oximetry Values

ctHb	123	g/dL	[12.0 - 16.0]
sO_2	92	%	[95.0 - 98.0]
FO_2Hb		%	[94.0 - 99.0]
FCOHb			[-]
FHHb		%	[-]
FmetHb		%	[0.02 - 0.06]
Hctc		%	

Electrolyte Values

cK+	3.7	mmol/L	[3.0 - 5.0]
cNa+	139	mmol/L	[136 - 146]
$cCa^{2}+$	1.12	mmeq/L	[1.15 - 1.29]
cCl-	103	mmol/L	[98 - 106]

Metabolite Values

cGlu	7.2	mmol/L	[3.5 - 10.0]
cLac	3.6	mmol/L	[0.5 - 1.6]

Acid Base Status

cBase(Ecf)c	-4.8	mmol/L
$cHCO^{3}$-(P,st)c	19	mmol/L

Notes
↑ Value (s) above reference range
↓ Value (s) below reference range
c Calculated Value (s)
e Estimated Value (s)

DEBRIEF DISCUSSION POINTS

- Challenges of donning and doffing PPE in ED environment – ensure all staff aware of the correct procedures to prevent contamination of 'clean' areas
- Management of an acutely unwell patient – can the team in PPE manage the whole situation, or do the limitations of movement and contact mean a second 'clean' team need to be able to manage logistics away from the patient?
- Movement of a patient with COVID-19 through a hospital – what procedures need to be activated from ED to achieve this safely?
- Where to safely manage acutely unwell patients requiring isolation – What are the staffing implications of this?
- Use of aerosolising procedures in a patient with COVID-19 – how to ensure staff safety and reduce spread of virus during the need for suction, Airvo use etc.
- Where is the best area to intubate and ventilate a child with COVID-19? – Balance of additional movement throughout a hospital vs. I&V in a non-ITU/theatres setting
- Equipment management – ensuring only the required equipment is exposed to the 'hot' environment so as to minimise waste and cleaning requirements
- Use of correct HME filters in ventilator
- Challenges to staff for performing procedures and extended time in PPE during acute management of an unwell child